Phaseline

Targets › CSF2

CSF2 (Granulocyte-macrophage colony-stimulating factor): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 3, 2 Phase 2; Oncology, Hematology, Immunology; next expected readout Dec 2026.

Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. (UniProt, P04141)

Open in Phaseline: the race on CSF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TJ BiopharmaPlonmarlimab
Granulocyte-macrophage colony-stimulating factor antagonist
CSF2Phase 3Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis; Acute Gouty ArthritisDec 2026
BriaCell TherapeuticsSV-BR-1-GM
Allogeneic whole cell breast tumor cell line transfected with CSF2 gene encoding GM-CSF; p
CSF2Phase 3Breast CancerDec 2027
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsGVAX Pancreas Vaccine
GM-CSF-transfected allogeneic pancreatic tumor cell vaccine
CSF2Phase 2Pancreatic Cancer–

Conditions

Breast Cancer (1) Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (1) Acute Gouty Arthritis (1) Pancreatic Cancer (1)

Modalities

mixed (3)

Companies

BriaCell Therapeutics (1) TJ Biopharma (1) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.